MRTFA and pulmonary hypertension: So far, MKL1 has been uniformly considered a promoter of disease progression by programming transcriptional events involved in pathological cardiac hypertrophy [26, 27], colitis [14], sepsis [15], pulmonary hypertension [11], atherosclerosis [28], diabetic nephropathy [29], cirrhosis [30], and carcinogenesis [31].